Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate

Author: Benzinga Newsdesk | March 27, 2025 04:03pm
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.90) by 28.89 percent. This is a 63.29 percent increase over losses of $(3.16) per share from the same period last year.

Posted In: IKT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist